High prevalence of artery disease along
with the rise in geriatric population will drive growth of the
overall drug eluting stents market
The rising old age population and the high
occurrence of coronary artery diseases are some of the major factors
which will propel the drug eluting stents market. Unhealthy dietary
habits, sedentary lifestyles, and lack of proper exercise have
resulted into the increased incidences of atherosclerosis. The demand
for DES is rising significantly as atherosclerosis is extensively
treated using DES. Additionally, constant decline in the price due to
technological advancements along with increased adoption of DES
across the globe is encouraging the acceptance of drug-eluting stent
in the management of arterial diseases.
Fill the form for an exclusive sample of Drug
Eluting Stents Market report @
https://www.coherentmarketinsights.com/insight/request-sample/207
In terms of geography, North America held the
maximum share in the global drug eluting stent market. Scientific
advancements such as the biodegradable stents have resulted in the
dominance of the market in this region. However, Asia Pacific drug
eluting stent market is likely to show a significant growth momentum
in the near future. Markets in countries such as China and India are
expected to record a considerable growth during the forecast period,
owing to the increase in patient awareness associated with
drug-eluting stents. Existence of large pool of old age population
who are susceptible to arterial diseases and the increasing frequency
of chronic diseases such as cardiac disorders and diabetes will drive
the overall drug eluting stents market.
In the
medical sector, a stent is a plastic or metal tube implanted into the
lumen of a duct or anatomic vessel to keep the passage of blood
vessels unobstructed. Stenting is the process of placement of a stent
into the body. Various stents are used for a variety of purposes,
from vascular and biliary stents, expandable coronary, relatively
simple stents made of plastic, which are used to allow the
uninterrupted flow of urine from the kidney to the bladder. A DES or
drug-eluting stent is a coronary or peripheral stent or a scaffold
that is usually placed into the tapering, diseased coronary or
peripheral arteries that release a drug slowly to block cell
proliferation. This process of stenting thwarts fibrosis that, along
with clots or thrombi, could block the stented coronary artery, a
process known as restenosis. Drug-eluting stents are usually placed
within the coronary or peripheral artery by an interventional
cardiologist or radiologist during an angioplasty process.
Drug-eluting stents were approved by the FDA after the scientific
trials showed that they were superior to the other metal stents for
the management of coronary artery narrowing and they have lower rates
of major cardiac events. The principle drug-eluting stents which were
approved in the U.S. and Europe were covered with an mTOR inhibitor,
or paclitaxel, such as sirolimus.
According to the data released by CDC in 2015,
around 610,000 people die of coronary diseases in the U.S. every
year, around 25% of the deaths caused by heart diseases. Also, CHD or
coronary heart disease was the key disease killing over 370, 000
people per year. The statistics also said that every year around
735,000 people in the U.S. experience a heart attack. Of these
735,000 individuals, 525,000 were first heart attacks and the rest
happened in patients who had already suffered from a heart attack.
Rise in the number of heart disease along with diseases related to
arterial narrowing such as renal artery stenosis will be responsible
for a steady growth of the drug-eluting stent market.
Drug Eluting Stents Market Taxonomy
On the basis of type of product, the global market
is classified into:
-
Polymer-free coatings
-
Polymer-based coatings
On the basis of application, the global market is
classified into:
-
Peripheral Artery Disease
-
Coronary Artery Disease
Request to view table of content @
https://www.coherentmarketinsights.com/ongoing-insight/toc/207
The drug
eluting stents market is highly fragmented, owing to the presence of
many well established companies. The rivalry among these vendors is
likely to increase with the rise in product diversifications,
technological innovations, mergers and acquisitions, and with the
introduction next-generation products. Some of the key players
operating the global drug eluting stents industry are Biosensors
International, Abbot Laboratories, Terumo, Boston Scientific,
Medtronic and Lepu Medical. Some of the other important companies in
the market are Biotronik, Envison Scientific, Stentys, MicroPosrt
Medical, Meril Lifesciences, Shandong JW Medical Systems and Opto
Circuits.
About Coherent Market Insights:
Coherent Market Insights is a
prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations
related to emerging market trends, technologies, and potential
absolute dollar opportunity
No comments:
Post a Comment